Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infections in
vaccinated individuals and reinfections in previously infected individuals have become …

The first approved dengue vaccine has now been licensed in six countries. We propose that
this live attenuated vaccine acts like a silent natural infection in priming or boosting host …

Background Large Phase III trials across Asia and Latin America have recently demonstrated
the efficacy of a recombinant, live-attenuated dengue vaccine (Dengvaxia) over the first 25 …

BACKGROUND First discovered in 1947, Zika virus (ZIKV) received little attention until a
surge in microcephaly cases was reported after a 2015 outbreak in Brazil. The size of the …

Biased seroprevalence estimates can occur using serological assays optimized with
validation sets unrepresentative of disease spectrum in the general population. Correct …

Many public health responses and modeled scenarios for COVID-19 outbreaks caused by
SARS-CoV-2 assume that infection results in an immune response that protects individuals …

The clinical outcomes associated with Zika virus (ZIKV) in the Americas have been well
documented, but other aspects of the pandemic, such as attack rates and risk factors, are poorly …

Interpretation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
serosurveillance studies is limited by poorly defined performance of antibody assays over time in …

As with many pathogens, most dengue infections are subclinical and therefore unobserved
1 . Coupled with limited understanding of the dynamic behaviour of potential serological …

We describe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T cell
responses, soluble markers of inflammation, and antibody levels and neutralization capacity …